Lexology February 26, 2020
Editor’s Note: In a recent webinar, Manatt explained the complexities of the 340B program, which requires drug manufacturers to provide outpatient drugs to eligible healthcare entities at sharply reduced prices. The webinar also reviewed key findings from Manatt’s 50-state survey on the interplay between the 340B and Medicaid programs. In part one of our article summarizing the webinar, published in our January “Health Update,” we reviewed the 340B and Medicaid Drug Rebate Programs, as well as examined the interplay between 340B and Medicaid. Part two of our summary, below, shares information on the 340B program’s growing scope, insights into two of 340B’s long-standing vulnerabilities, key findings from our 50-state 340B survey and a look ahead to what’s next. Click here...
Today's Sponsors
Today's Sponsor